These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 27187785)

  • 1. Safety considerations when treating myelofibrosis.
    O'Sullivan JM; McLornan DP; Harrison CN
    Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
    Saeed I; McLornan D; Harrison CN
    Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
    Jain T; Mesa R
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How many JAK inhibitors in myelofibrosis?
    Ferreira BV; Harrison C
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
    Tremblay D; Mascarenhas J
    Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pacritinib: a new agent for the management of myelofibrosis?
    Beauverd Y; McLornan DP; Harrison CN
    Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
    Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
    Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Momelotinib in myelofibrosis.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Fragliasso V; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Pharmacother; 2024 Apr; 25(5):521-528. PubMed ID: 38623844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [JAK inhibitors for myelofibrosis: ruxolitinib and momelotinib].
    Kosugi H
    Rinsho Ketsueki; 2024; 65(8):798-809. PubMed ID: 39231711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
    England JT; Gupta V
    Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
    Hunter AM; Bose P
    Expert Opin Pharmacother; 2024 Jul; 25(10):1391-1404. PubMed ID: 39067001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Momelotinib: Mechanism of action, clinical, and translational science.
    Vlasakakis G; McCabe MT; Ho YL; Ferron-Brady G; Martin P; Bentley D; Ellis C; Antonysamy M; Visser SAG
    Clin Transl Sci; 2024 Aug; 17(8):e70018. PubMed ID: 39189872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
    Diaz AE; Mesa RA
    Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.